Given that CAMKV is highly enriched in NB cells and tumors, we speculate that novel small molecule inhibitors to specifically suppress the DYRK3/CAMKV module could constitute an innovative therapeutic strategy to fight high-risk neuroblastoma in a very precise and effective manner, a topic that will be the subject of our future efforts. The gene discussed is DYRK3; the disease is neuroblastoma.